Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer’s Disease

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder causing progressive memory loss and cognitive dysfunction. Anti-AD strategies targeting cell receptors consider them as isolated units. However, many cell surface receptors cooperate and physically contact each other forming complexes having different biochemical properties than individual receptors. We here report the discovery of dopamine D, histamine H, and N-methyl-D-aspartate (NMDA) glutamate receptor heteromers in heterologous systems and in rodent brain cortex. Heteromers were detected by co-immunoprecipitation and in situ proximity ligation assays (PLA) in the rat cortex where H receptor agonists, via negative cross-talk, and H receptor antagonists, via cross-antagonism, decreased D receptor agonist signaling determined by ERK1/2 or Akt phosphorylation, and counteracted D receptor-mediated excitotoxic cell death. Both D and H receptor antagonists also counteracted NMDA toxicity suggesting a complex interaction between NMDA receptors and D-H receptor heteromer function. Likely due to heteromerization, H receptors act as allosteric regulator for D and NMDA receptors. By bioluminescence resonance energy transfer (BRET), we demonstrated that D or H receptors form heteromers with NR1A/NR2B NMDA receptor subunits. D-H-NMDA receptor complexes were confirmed by BRET combined with fluorescence complementation. The endogenous expression of complexes in mouse cortex was determined by PLA and similar expression was observed in wild-type and APP/PS1 mice. Consistent with allosteric receptor-receptor interactions within the complex, H receptor antagonists reduced NMDA or D receptor-mediated excitotoxic cell death in cortical organotypic cultures. Moreover, H receptor antagonists reverted the toxicity induced by ß-amyloid peptide. Thus, histamine H receptors in D-H-NMDA heteroreceptor complexes arise as promising targets to prevent neurodegeneration.

The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases

“…In this study, a statistically significant positive correlation of D1R density and BACE1 mRNA transcriptional expression in the caudate of AD was observed. This suggests that D1R hypersensitivity is mediated by a complex interaction between N ‐methyl‐ d ‐aspartate receptors and dopamine D1‐histamine H 3 receptor heteromer (Rodriguez‐Ruiz et al ). Subsequently, our understanding of D1R activation mechanism in BACE1 activity needs to be further clarified.…”

Synthesis and biological evaluation of heteroalicyclic cyanoguanidines at histamine receptors

“…The first antihistamines at the histamine H 1 receptor (H 1 R) were already developed in the early 1930s and are still used for the treatment of histamine‐mediated allergic conditions . While H 2 R antagonists have been successfully used for the treatment of peptic ulcers, H 3 R is widely expressed in the central nervous system (CNS) and is still a potential drug target for, for example, neurodegenerative diseases . In 2016, Pitolisant became the first marketed histamine H 3 R inverse agonist/antagonist for the treatment of narcolepsy .…”

Pharmacological andSARanalysis of theLINS01 compounds at the human histamine H1, H2, and H3receptors

“…H 3 R antagonists have been investigated as potential treatments for several CNS disorders, including sleep disorders, schizophrenia, epilepsy, attention deficit, hyperactivity disorder, and even obesity. There is also potential for H 3 R antagonists to have effects in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's chorea . Recently, a H 3 R antagonist (pitolisant) has been approved for the maintenance of wakefulness in patients with narcolepsy .…”